FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

José Jimeno

Research Profile

Chemicals & Drugs

Procedures

Anatomy

Tumor Cells, Cultured

Concepts & Ideas

Disorders

Physiology

Living Beings

Mouse

Co-author Network

Publications

TOP 3
Maria Serova; Maria Eugenia Riveiro; Miguel Aracil; Ivan Bieche; Armand de Gramont; Sandrine Faivre; Carlos Maria Galmarini; José Jimeno; Eric Raymond
Predictive factors of sensitivity to elisidepsin, a novel kahalalide f-derived marine compound.
Federica Grosso; R Sanfilippo; E Virdis; C Piovesan; Paola Collini; Palma Dileo; C Morosi; J C Tercero; José Jimeno; Maurizio D'Incalci; Alessandro Gronchi; Silvana Pilotti; Paolo G Casali
Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.
R Humeniuk; Lata G Menon; Prasun Mishra; G Saydam; G S A Longo-Sorbello; Y Elisseyeff; L D Lewis; Miguel Aracil; José Jimeno; Joseph R Bertino; Debabrata Banerjee
Aplidin synergizes with cytosine arabinoside: functional relevance of mitochondria in Aplidin-induced cytotoxicity.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of José Jimeno (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Maria Serova; Maria Eugenia Riveiro; Miguel Aracil; Ivan Bieche; Armand de Gramont; Sandrine Faivre; Carlos Maria Galmarini; José Jimeno; Eric Raymond
Predictive factors of sensitivity to elisidepsin, a novel kahalalide f-derived marine compound.
Marine drugs 2013;11(3):944-59.
2009: Federica Grosso; R Sanfilippo; E Virdis; C Piovesan; Paola Collini; Palma Dileo; C Morosi; J C Tercero; José Jimeno; Maurizio D'Incalci; Alessandro Gronchi; Silvana Pilotti; Paolo G Casali
Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(8):1439-44.
2007: R Humeniuk; Lata G Menon; Prasun Mishra; G Saydam; G S A Longo-Sorbello; Y Elisseyeff; L D Lewis; Miguel Aracil; José Jimeno; Joseph R Bertino; Debabrata Banerjee
Aplidin synergizes with cytosine arabinoside: functional relevance of mitochondria in Aplidin-induced cytotoxicity.
Leukemia 2007;21(12):2399-405.
2007: Federica Grosso; Robin L Jones; George D Demetri; Ian R Judson; Jean-Yves Blay; Axel Le Cesne; Roberta Sanfilippo; Paola Casieri; Paola Collini; Palma Dileo; Carlo Spreafico; Silvia Stacchiotti; Elena Tamborini; Juan C Tercero; José Jimeno; Maurizio D'Incalci; Alessandro Gronchi; Jonathan A Fletcher; Silvana Pilotti; Paolo G Casali
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
The lancet oncology 2007;8(7):595-602.
2007: Victoria Moneo; Beatriz G Serelde; Juan F M Leal; Carmen Blanco-Aparicio; Ramon Diaz-Uriarte; Miguel Aracil; Juan C Tercero; José Jimeno; Amancio Carnero
Levels of p27(kip1) determine Aplidin sensitivity.
Molecular cancer therapeutics 2007;6(4):1310-6.
2007: Victoria Moneo; Beatriz G Serelde; Jesús Fominaya; Juan F M Leal; Carmen Blanco-Aparicio; Lourdes Romero; Margarita Sánchez-Beato; Juan C Cigudosa; Juan C Tercero; Miguel A Piris; José Jimeno; Amancio Carnero
Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53.
Journal of cellular biochemistry 2007;100(2):339-48.
2006: Federica Grosso; Palma Dileo; R Sanfilippo; Silvia Stacchiotti; Rossella Bertulli; C Piovesan; José Jimeno; Maurizio D'Incalci; A Gescher; Paolo G Casali
Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.
European journal of cancer (Oxford, England : 1990) 2006;42(10):1484-90.
2006: Laurent Zelek; Alejandro Yovine; Etienne Brain; Francois Turpin; Abdelkrim Taamma; M Riofrio; Marc Spielmann; José Jimeno; Jean-Louis Misset
A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer.
British journal of cancer 2006;94(11):1610-4.
2006: José Jimeno; Miguel Aracil; Juan C Tercero
Adding pharmacogenomics to the development of new marine-derived anticancer agents.
Journal of translational medicine 2006;4():3.
2005: Gianluca Tognon; Sergio Bernasconi; Nicola Celli; Glynn Faircloth; Carmen Cuevas; José Jimeno; Eugenio Erba; Maurizio D'Incalci
Induction of resistance to Aplidin in a human ovarian cancer cell line related to MDR expression.
Cancer biology & therapy 2005;4(12):1325-30.
2005: Sandrine Faivre; Jose A Lopez-Martin; Catherine Delbaldo; Nora Ady-Vago; Cecilia Guzman; Luis Lopez-Lazaro; Stéphanie Lozahic; José Jimeno; Fernando Pico; Jean-Pierre Armand; José Antonio Lopez Martin; Eric Raymond
Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(31):7871-80.
2005: Anna Riccardi; Daniela Meco; Paolo Ubezio; Giorgio Mazzarella; Mirko Marabese; Glynn Faircloth; José Jimeno; Maurizio D'Incalci; Riccardo Riccardi
Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft.
Anti-cancer drugs 2005;16(8):811-5.
2005: Rocio Garcia-Carbonero; Jeffrey G Supko; ROBERT G MAKI; Judith Manola; David P Ryan; David Harmon; Thomas A Puchalski; G Goss; Michael Seiden; A Waxman; M Travis Quigley; T Lopez; M A Sancho; José Jimeno; Cecilia Guzman; George D Demetri
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(24):5484-92.
2005: Nerea Martínez; Margarita Sánchez-Beato; Amancio Carnero; Victoria Moneo; Juan C Tercero; Isabel Fernández; Mercedes Navarrete; José Jimeno; Miguel A Piris
Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients.
Molecular cancer therapeutics 2005;4(5):814-23.
2005: Jeany M Rademaker-Lakhai; Simon Horenblas; Wim Meinhardt; Ellen Stokvis; Theo M de Reijke; José Jimeno; Luis Lopez-Lazaro; Jose A Lopez-Martin; Jos H Beijnen; Jan H M Schellens
Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(5):1854-62.
2005: Axel Le Cesne; Jean-Yves Blay; Ian Judson; Allan van Oosterom; Jaap Verweij; John Radford; Paul Lorigan; S Rodenhuis; ISABELLE RAY COQUARD; Sylvie Bonvalot; Françoise Collin; José Jimeno; Eugenio Donato Di Paola; Martine Van Glabbeke; Ole Steen Nielsen
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(3):576-84.
2004: Sarah Donald; Richard D Verschoyle; Peter Greaves; Tina Colombo; Massimo Zucchetti; Cristiano Falcioni; Marco Zaffaroni; Maurizio D'Incalci; Margaret M Manson; José Jimeno; William P Steward; Andreas J Gescher
Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectidin) without compromising efficacy in a rat mammary carcinoma.
International journal of cancer. Journal international du cancer 2004;111(6):961-7.
2004: Rocio Garcia-Carbonero; Jeffrey G Supko; Judith Manola; Michael Seiden; David Harmon; David P Ryan; M Travis Quigley; P Merriam; J Canniff; G Goss; Ursula Matulonis; ROBERT G MAKI; T Lopez; Thomas A Puchalski; M A Sancho; J Gomez; Cecilia Guzman; José Jimeno; George D Demetri
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(8):1480-90.
2004: José Jimeno; Jose A Lopez-Martin; Ana Ruiz-Casado; M A Izquierdo; P J Scheuer; K Rinehart
Progress in the clinical development of new marine-derived anticancer compounds.
Anti-cancer drugs 2004;15(4):321-9.
2004: Sarah Donald; Richard D Verschoyle; Peter Greaves; Samantha Orr; José Jimeno; Andreas J Gescher
Comparison of four modulators of drug metabolism as protectants against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the female rat and in hepatocytes in vitro.
Cancer chemotherapy and pharmacology 2004;53(4):305-12.
2004: Alejandro Yovine; M Riofrio; Jean-Yves Blay; Etienne Brain; Jérôme Alexandre; Carmen Kahatt; Abdelkrim Taamma; José Jimeno; C Martin; Y Salhi; Esteban Cvitkovic; Jean-Louis Misset
Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):890-9.
2004: Rolf W Sparidans; Jan H M Schellens; Luis López-Lázaro; José Jimeno; Jos H Beijnen
Liquid chromatographic assay for the cyclic depsipeptide aplidine, a new marine antitumor drug, in whole blood using derivatization with trans-4'-hydrazino-2-stilbazole.
Biomedical chromatography : BMC 2004;18(1):16-20.
2003: Susana G Gómez; Juan A. Bueren; Glynn Faircloth; José Jimeno; Beatriz Albella
In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells.
Experimental hematology 2003;31(11):1104-11.
2003: Maurizio D'Incalci; José Jimeno
Preclinical and clinical results with the natural marine product ET-743.
Expert opinion on investigational drugs 2003;12(11):1843-53.
2003: Sarah Donald; Richard D Verschoyle; Peter Greaves; Timothy W Gant; Tina Colombo; Marco Zaffaroni; Roberta Frapolli; Massimo Zucchetti; Maurizio D'Incalci; Daniela Meco; Riccardo Riccardi; Luis Lopez-Lazaro; José Jimeno; Andreas J Gescher
Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat.
Cancer research 2003;63(18):5902-8.
2003: Maurizio D'Incalci; Tina Colombo; Paolo Ubezio; Ines Nicoletti; Raffaella Giavazzi; Eugenio Erba; L Ferrarese; Daniela Meco; Riccardo Riccardi; C Sessa; E Cavallini; José Jimeno; Glynn Faircloth
The combination of yondelis and cisplatin is synergistic against human tumor xenografts.
European journal of cancer (Oxford, England : 1990) 2003;39(13):1920-6.
2003: Chris Twelves; K Hoekman; Adrian Bowman; Jan B Vermorken; Alan Anthoney; J Smyth; Charlotte van Kesteren; Jos H Beijnen; J Uiters; Jantien Wanders; J Gomez; C Guzmán; José Jimeno; Axel R Hanauske
Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 2003;39(13):1842-51.
2003: Eugenio Erba; Marta Serafini; Giuseppe Gaipa; Gianluca Tognon; Sergio Marchini; Nicola Celli; Domenico Rotilio; Massimo Broggini; José Jimeno; Glynn Faircloth; Andrea Biondi; Maurizio D'Incalci
Effect of Aplidin in acute lymphoblastic leukaemia cells.
British journal of cancer 2003;89(4):763-73.
2003: Caroline Laverdiere; E Anders Kolb; Jeffrey G Supko; Richard Gorlick; Paul A Meyers; ROBERT G MAKI; Leonard H Wexler; George D Demetri; John Healey; Andrew G Huvos; Allen M Goorin; Rochelle Bagatell; Ana Ruiz-Casado; Cecilia Guzman; José Jimeno; David Harmon
Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma.
Cancer 2003;98(4):832-40.
2003: Charlotte van Kesteren; M M M de Vooght; Luis López-Lázaro; Ron A A Mathôt; J H M Schellens; José Jimeno; Jos H Beijnen
Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.
Anti-cancer drugs 2003;14(7):487-502.
2003: Massimo Broggini; Sergio Marchini; Emanuela Galliera; Patrizia Borsotti; Giulia Taraboletti; Eugenio Erba; Marina Sironi; José Jimeno; Glynn Faircloth; Raffaella Giavazzi; Maurizio D'Incalci
Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4.
Leukemia 2003;17(1):52-9.
2002: Thomas A Puchalski; David P Ryan; Rocio Garcia-Carbonero; George D Demetri; Leah Butkiewicz; David Harmon; Michael Seiden; ROBERT G MAKI; Luis Lopez-Lazaro; José Jimeno; Cecilia Guzman; Jeffrey G Supko
Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity.
Cancer chemotherapy and pharmacology 2002;50(4):309-19.
2002: Ellen Stokvis; Hilde Rosing; Luis López-Lázaro; I Rodriguez; José Jimeno; J G Supko; J H M Schellens; Jos H Beijnen
Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry.
Journal of mass spectrometry : JMS 2002;37(9):992-1000.
2002: Beatriz Albella; Glynn Faircloth; Luis López-Lázaro; C Guzmán; José Jimeno; Juan A. Bueren
In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results.
European journal of cancer (Oxford, England : 1990) 2002;38(10):1395-404.
2002: Eugenio Erba; L Bassano; G Di Liberti; Ivan Muradore; giovanna chiorino; Paolo Ubezio; Sara Vignati; Annamaria Codegoni; Maria Alfonsina Desiderio; Glynn Faircloth; José Jimeno; Maurizio D'Incalci
Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine.
British journal of cancer 2002;86(9):1510-7.
2002: Charlotte van Kesteren; Chris Twelves; Adrian Bowman; Klaas Hoekman; Luis López-Lázaro; José Jimeno; Cecilia Guzman; Ron A A Mathôt; Andrew Simpson; Jan B Vermorken; John Smyth; Jan H M Schellens; Michel J X Hillebrand; Hilde Rosing; Jos H Beijnen
Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.
Anti-cancer drugs 2002;13(4):381-93.
2002: David P Ryan; Thomas A Puchalski; Jeffrey G Supko; David Harmon; ROBERT G MAKI; Rocio Garcia-Carbonero; Caroline Kuhlman; Jennifer Winkelman; Priscilla Merriam; Travis Quigley; José Jimeno; Judith Manola; George D Demetri
A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.
The oncologist 2002;7(6):531-8.
2002: Maurizio D'Incalci; Eugenio Erba; Giovanna Damia; Emanuela Galliera; Laura Carrassa; Sergio Marchini; Roberto Mantovani; Gianluca Tognon; Robert Fruscio; José Jimeno; Glynn Faircloth
Unique features of the mode of action of ET-743.
The oncologist 2002;7(3):210-6.
2002: Miguel A Villalona-Calero; S Gail Eckhardt; Geoffrey Weiss; Manuel Hidalgo; Jos H Beijnen; Charlotte van Kesteren; Hilde Rosing; Elizabeth Campbell; Maura Kraynak; Luis Lopez-Lazaro; Cecilia Guzman; Daniel Von Hoff; José Jimeno; Eric K Rowinsky
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(1):75-85.
2001: Charlotte van Kesteren; R A Mathĵt; Luis López-Lázaro; Esteban Cvitkovic; Abdelkrim Taamma; José Jimeno; Cecilia Guzman; J H M Schellens; Jean-Louis Misset; Etienne Brain; Michel J X Hillebrand; Hilde Rosing; Jos H Beijnen
A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion.
Cancer chemotherapy and pharmacology 2001;48(6):459-66.
2001: Bastiaan Nuijen; Marjan Bouma; Herre Talsma; Consuelo Manada; José Jimeno; Luis Lopez-Lazaro; Auke Bult; Jos H Beijnen
Development of a lyophilized parenteral pharmaceutical formulation of the investigational polypeptide marine anticancer agent kahalalide F.
Drug development and industrial pharmacy 2001;27(8):767-80.
2001: Rolf W Sparidans; Hilde Rosing; Michel J X Hillebrand; Luis López-Lázaro; José Jimeno; Ignasio Manzanares; Charlotte van Kesteren; Esteban Cvitkovic; A T van Oosterom; J H M Schellens; Jos H Beijnen
Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man.
Anti-cancer drugs 2001;12(8):653-66.
2001: Wei-Wei Li; Naoto Takahashi; Suresh C Jhanwar; Carlos Cordon-Cardo; Y Elisseyeff; José Jimeno; Glynn Faircloth; Joseph R Bertino
Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(9):2908-11.
2001: J Luber-Narod; B Smith; W Grant; José Jimeno; Luis López-Lázaro; Glynn Faircloth
Evaluation of the use of in vitro methodologies as tools for screening new compounds for potential in vivo toxicity.
Toxicology in vitro : an international journal published in association with BIBRA 2001;15(4-5):571-7.
2001: Susana G Gómez; Glynn Faircloth; Luis López-Lázaro; José Jimeno; Juan A. Bueren; Beatriz Albella
In vitro hematotoxicity of Aplidine on human bone marrow and cord blood progenitor cells.
Toxicology in vitro : an international journal published in association with BIBRA 2001;15(4-5):347-50.
2001: Rolf W Sparidans; Ellen Stokvis; José Jimeno; Luis López-Lázaro; J H M Schellens; Jos H Beijnen
Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F.
Anti-cancer drugs 2001;12(7):575-82.
2001: Bastiaan Nuijen; Marjan Bouma; Consuelo Manada; José Jimeno; Auke Bult; Jos H Beijnen
In vitro hemolysis and buffer capacity studies with the novel marine anticancer agent kahalalide F and its reconstitution vehicle cremophor EL/ethanol.
PDA journal of pharmaceutical science and technology / PDA 2001;55(4):223-9.
2001: Abdelkrim Taamma; Jean-Louis Misset; M Riofrio; Cecilia Guzman; Etienne Brain; Luis Lopez-Lazaro; Hilde Rosing; José Jimeno; Esteban Cvitkovic
Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1256-65.
2001: Suzette Delaloge; Alejandro Yovine; Abdelkrim Taamma; M Riofrio; Etienne Brain; Eric Raymond; Paul-Henri Cottu; François Goldwasser; José Jimeno; Jean-Louis Misset; Michel Marty; Esteban Cvitkovic
Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1248-55.
2001: Bastiaan Nuijen; Marjan Bouma; Consuelo Manada; José Jimeno; L L Lazaro; Auke Bult; Jos H Beijnen
Compatibility and stability of the investigational polypeptide marine anticancer agent kahalalide F in infusion devices.
Investigational new drugs 2001;19(4):273-81.
2000: Charlotte van Kesteren; Esteban Cvitkovic; Abdelkrim Taamma; Luis López-Lázaro; José Jimeno; Cecilia Guzman; R A Math t; J H M Schellens; Jean-Louis Misset; Etienne Brain; Michel J X Hillebrand; Hilde Rosing; Jos H Beijnen
Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(12):4725-32.
2000: Bastiaan Nuijen; Marjan Bouma; Consuelo Manada; José Jimeno; J H M Schellens; Auke Bult; Jos H Beijnen
Pharmaceutical development of anticancer agents derived from marine sources.
Anti-cancer drugs 2000;11(10):793-811.
2000: Bastiaan Nuijen; Marjan Bouma; RE Henrar; Pablo Floriano; José Jimeno; Herre Talsma; J Jantina Kettenes-van den Bosch; albert heck; Auke Bult; Jos H Beijnen
Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine.
PDA journal of pharmaceutical science and technology / PDA 2000;54(3):193-208.
2000: Eugenio Erba; D Bergamaschi; L Bassano; Simona Ronzoni; G Di Liberti; Ivan Muradore; Sara Vignati; Glynn Faircloth; José Jimeno; Maurizio D'Incalci
Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743).
British journal of cancer 2000;82(10):1732-9.
1999: Rolf W Sparidans; J Jantina Kettenes-van den Bosch; Olaf van Tellingen; B Nuyen; RE Henrar; José Jimeno; Glynn Faircloth; Pablo Floriano; K L Rinehart; Jos H Beijnen
Bioanalysis of aplidine, a new marine antitumoral depsipeptide, in plasma by high-performance liquid chromatography after derivatization with trans-4-hydrazino-2-stilbazole.
Journal of chromatography. B, Biomedical sciences and applications 1999;729(1-2):43-53.
1999: Eugenio Erba; D Bergamaschi; Simona Ronzoni; Mario Faretta; S Taverna; M Bonfanti; Carlo V Catapano; Glynn Faircloth; José Jimeno; Maurizio D'Incalci
Mode of action of thiocoraline, a natural marine compound with anti-tumour activity.
British journal of cancer 1999;80(7):971-80.
1999: Rolf W Sparidans; RE Henrar; José Jimeno; Glynn Faircloth; Pablo Floriano; Jos H Beijnen
Bioanalysis of thiocoraline, a new marine antitumoral depsipeptide, in plasma by high-performance liquid chromatography and fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 1999;726(1-2):255-60.
1999: D Bergamaschi; Simona Ronzoni; S Taverna; Mario Faretta; P De Feudis; Glynn Faircloth; José Jimeno; Eugenio Erba; Maurizio D'Incalci
Cell cycle perturbations and apoptosis induced by isohomohalichondrin B (IHB), a natural marine compound.
British journal of cancer 1999;79(2):267-77.
1998: Hilde Rosing; Michel J X Hillebrand; José Jimeno; A Gómez; Pablo Floriano; Glynn Faircloth; RE Henrar; Jan B Vermorken; Esteban Cvitkovic; Auke Bult; Jos H Beijnen
Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal of mass spectrometry : JMS 1998;33(11):1134-40.
1998: Michele Ghielmini; E Colli; Eugenio Erba; D Bergamaschi; Sandro Pampallona; José Jimeno; Glynn Faircloth; Cristiana Sessa
In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(9):989-93.
1998: Hilde Rosing; Michel J X Hillebrand; José Jimeno; A Gómez; Pablo Floriano; Glynn Faircloth; L Cameron; RE Henrar; Jan B Vermorken; Auke Bult; Jos H Beijnen
Analysis of Ecteinascidin 743, a new potent marine-derived anticancer drug, in human plasma by high-performance liquid chromatography in combination with solid-phase extraction.
Journal of chromatography. B, Biomedical sciences and applications 1998;710(1-2):183-9.
1997: D Bergamaschi; Mario Faretta; Simona Ronzoni; S Taverna; P De Feudis; M Bonfanti; G Guidi; M Faircloth; José Jimeno; Maurizio D'Incalci; Eugenio Erba
Flow cytometric analysis of cell cycle phase perturbations induced by Thiocoraline, a new marine-derived anticancer compound.
European journal of histochemistry : EJH 1997;41 Suppl 2():63-4.